There was a significant difference in the proportion of TILs by tumor intrinsic subtype, with a significantly higher proportion of TILs in nonluminal (ie, basal-like and HER2-enriched) compared with luminal tumors (CALGB 40601 trial: median nonluminal tumors = 25 [IQR, 15-60], median luminal tumors = 20 [IQR, 10-30], P = .01; PAMELA trial: median nonluminal tumors = 30 [IQR, 20-60], median luminal tumors = 20 [IQR, 10-30], P = .004; combined cohort: median nonluminal tumors = 30 [IQR, 15-60], median luminal tumors = 20 [IQR, 10-30], P < .001) (eFigure 3B and D in the Supplement; Figure 1B). This evidence concerns the gene ERBB2 and neoplasm.